ADMA Biologics, Inc.

NGM: ADMA

Live Quote

📈 ZcoreAI Score

Our AI model analyzes ADMA Biologics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.

Get ADMA Z-Score →

About ADMA Biologics, Inc.

Healthcare Biotechnology

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

📊 Fundamental Analysis

ADMA Biologics, Inc. demonstrates exceptional profitability, with a profit margin of 28.8%.

The company recently reported 15.9% revenue growth, which is above average for the Healthcare sector.

Return on Equity (ROE) is 35.6%, which reflects exceptional capital efficiency.

At a current price of $9.70, ADMA currently trades near the bottom of its 52-week range (13%), indicating potential value or weakness (Range: $7.21 - $25.67).

💰 Valuation Insight

ADMA trades at a 35.3% discount (PE: 16.17), which may represent a value opportunity given the sector average of 25.00. Analysts expect earnings growth, as indicated by a lower forward PE.

🏥 Financial Health

✅ Profit Margin Excellent

🔴 Debt/Equity Elevated

✅ Revenue Growth Excellent

✅ Return on Equity Excellent

⚠️ Beta (Risk) Moderate Volatility

Key Financials

Market Cap

$2.31B

Trailing P/E

16.17

Forward P/E

7.03

Beta (5Y)

0.82

52W High

$25.67

52W Low

$7.21

Avg Volume

5.14M

Day High

Day Low

Get ADMA Z-Score on Dashboard 🚀